Pictet Asset Management Holding SA Buys 31,842 Shares of Kenvue Inc. $KVUE

Pictet Asset Management Holding SA grew its stake in Kenvue Inc. (NYSE:KVUE) by 2.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,145,115 shares of the company’s stock after buying an additional 31,842 shares during the period. Pictet Asset Management Holding SA owned approximately 0.06% of Kenvue worth $20,223,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in KVUE. Johnson Financial Group Inc. purchased a new stake in shares of Kenvue during the 2nd quarter valued at $26,000. CoreCap Advisors LLC lifted its holdings in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the last quarter. GK Wealth Management LLC purchased a new position in Kenvue in the third quarter worth $27,000. Bell Investment Advisors Inc purchased a new position in Kenvue in the second quarter worth $35,000. Finally, Keating Financial Advisory Services Inc. purchased a new position in Kenvue in the second quarter worth $38,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on KVUE. Barclays increased their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. HSBC cut their price objective on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, UBS Group raised their price objective on Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a report on Monday, November 2nd. Ten equities research analysts have rated the stock with a Hold rating. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $19.29.

Kenvue Stock Performance

Shares of KVUE opened at $19.31 on Thursday. The firm has a market cap of $37.09 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a fifty-two week low of $14.06 and a fifty-two week high of $20.13. The firm has a 50 day moving average price of $18.43 and a 200-day moving average price of $18.27.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.29. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. During the same quarter in the prior year, the company earned $0.28 EPS. The firm’s revenue was up 3.2% on a year-over-year basis. As a group, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is presently 95.45%.

Kenvue Profile

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.